EUVIMEDEUVIMED entdecken
Crossref

Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicity

April T Moy, Lia E D'Angelo, Daniel L Hertz

Pharmacogenetics and Genomics · 2026

DOI: 10.1097/fpc.0000000000000613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacogenetics and Genomics, 2026. Verfasst von April T Moy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Protein Kinase Inhibitors, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP1A2. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Associations between genetically predicted activity of metabolic enzymes and risks of adverse events from tyrosine kinase inhibitors (TKIs) may inform dosing to optimize treatment outcomes in patients with cancer. The goal of this study is to investigate the associations between UGT1A1, CYP3A4, and CYP1A2 activity and toxicity from nilotinib and pazopanib treatment. A retrospective pharmacogenetic association study was conducted in 117 participants of the Michigan Genomics Initiative who received pazopanib ( n = 103) or nilotinib ( n = 14). Clinical information, including patients’ disease, treatment, and toxicity was collected via retrospective review of medical records. No associations were found between the genetically predicted activity of any of the three enzymes and the composite endpoint of severe toxicity or treatment modifications because of toxicity. In the secondary hypothesis-generating analyses, patients with reduced UGT1A1 activity had an increased incidence of increased aspartate aminotransferase/alanine aminotransferase (44 vs. 25%; P = 0.034) and hypertension (52 vs. 31%; P = 0.024). In addition, patients with increased CYP1A2 activity from carrying CYP1A2*1F had a lower incidence of severe toxicity from pazopanib ( β -coefficient = ‐0.163, 95% confidence interval: ‐0.19 to ‐0.14, P = 0.008). Future investigations are needed to confirm these associations and determine whether personalized TKI treatment can optimize therapeutic outcomes in patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronosyltransferaseProtein Kinase InhibitorsCytochrome P-450 CYP3ACytochrome P-450 CYP1A2NeoplasmsHumansIndazolesPyrimidinesFemaleUGT1A1 EnzymeSulfonamidesMaleMiddle AgedAgedRetrospective StudiesGenotype

Stichwörter der Autor:innen

CYP1A2CYP3A4Michigan Genomics InitiativeUGT1A1nilotinibpazopanibpharmacogenetic

Substanzen

GlucuronosyltransferaseProtein Kinase InhibitorsIndazolesPyrimidinespazopanibUGT1A1 EnzymeSulfonamidesnilotinibCytochrome P-450 CYP3ACytochrome P-450 CYP1A2

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.

Zitieren

APA

Moy, A. T., D'Angelo, L. E., & Hertz, D. L. (2026). Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicity. Pharmacogenetics and Genomics. https://doi.org/10.1097/fpc.0000000000000613

Vancouver

Moy AT, D'Angelo LE, Hertz DL. Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicity. Pharmacogenetics and Genomics. 2026. doi:10.1097/fpc.0000000000000613

BibTeX
@article{Moy2026,
  author = {Moy, April T and D'Angelo, Lia E and Hertz, Daniel L},
  title = {Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicity},
  journal = {Pharmacogenetics and Genomics},
  year = {2026},
  doi = {10.1097/fpc.0000000000000613}
}
Kostenlos starten →